Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
US |
|
North American Construction Group Ltd
TSX:NOA
|
CA |
|
E
|
Everest Re Group Ltd
F:ERE
|
BM |
|
C
|
Cooper-Standard Holdings Inc
SWB:C31
|
US |
|
K
|
Konami Holdings Corp
XBER:KOA
|
JP |
|
V
|
Vector Group Ltd
XBER:VGR
|
US |
|
M
|
Macy's Inc
DUS:FDO
|
US |
|
Toyota Motor Corp
NYSE:TM
|
JP |
|
S
|
Sea Ltd
F:931
|
SG |
|
Nebius Group NV
NASDAQ:NBIS
|
NL |
|
P
|
Palo Alto Networks Inc
F:5AP
|
US |
|
B
|
Barclays PLC
XMUN:BCY
|
UK |
|
H
|
Heineken Holding NV
F:4H5
|
NL |
|
Alimentation Couche-Tard Inc
F:CJA1
|
CA |
|
A
|
Alphabet Inc
SWB:ABEC
|
US |
|
3
|
3M Co
SIX:MMM
|
US |
|
M
|
Meta Platforms Inc
F:FB2A
|
US |
|
G
|
Getlink SE
F:TNU3
|
FR |
|
Janus Living Inc
NYSE:JAN
|
US |
|
Copart Inc
NASDAQ:CPRT
|
US |
|
A
|
Advanced Micro Devices Inc
XMUN:AMD
|
US |
|
L
|
Lonza Group AG
XMUN:LO3
|
CH |
Wall St Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for SUPN is 64.77 USD with a low forecast of 55.55 USD and a high forecast of 70.35 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SUPN's stock price target?
Price Target
64.77
USD
According to Wall Street analysts, the average 1-year price target for SUPN is 64.77 USD with a low forecast of 55.55 USD and a high forecast of 70.35 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
